DE60226126D1 - Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen - Google Patents

Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen

Info

Publication number
DE60226126D1
DE60226126D1 DE60226126T DE60226126T DE60226126D1 DE 60226126 D1 DE60226126 D1 DE 60226126D1 DE 60226126 T DE60226126 T DE 60226126T DE 60226126 T DE60226126 T DE 60226126T DE 60226126 D1 DE60226126 D1 DE 60226126D1
Authority
DE
Germany
Prior art keywords
gamma
inhibitors
treatment
degenerative diseases
chronic degenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60226126T
Other languages
English (en)
Other versions
DE60226126T2 (de
Inventor
Hans Weiher
Helmut Sies
Guenter Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GTX Pharmaceuticals GmbH
Original Assignee
GTX Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTX Pharmaceuticals GmbH filed Critical GTX Pharmaceuticals GmbH
Publication of DE60226126D1 publication Critical patent/DE60226126D1/de
Application granted granted Critical
Publication of DE60226126T2 publication Critical patent/DE60226126T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60226126T 2001-02-20 2002-02-20 Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen Expired - Fee Related DE60226126T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01104063 2001-02-20
EP01104063 2001-02-20
PCT/EP2002/001799 WO2002066047A1 (en) 2001-02-20 2002-02-20 Use of $g(g)-gt inhibitors for the treatment of degenerative diseases

Publications (2)

Publication Number Publication Date
DE60226126D1 true DE60226126D1 (de) 2008-05-29
DE60226126T2 DE60226126T2 (de) 2009-05-07

Family

ID=8176542

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226126T Expired - Fee Related DE60226126T2 (de) 2001-02-20 2002-02-20 Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen

Country Status (4)

Country Link
EP (1) EP1361885B1 (de)
AT (1) ATE392213T1 (de)
DE (1) DE60226126T2 (de)
WO (1) WO2002066047A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types

Also Published As

Publication number Publication date
EP1361885A1 (de) 2003-11-19
DE60226126T2 (de) 2009-05-07
ATE392213T1 (de) 2008-05-15
EP1361885B1 (de) 2008-04-16
WO2002066047A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
EP1485381B8 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
WO2003080582A3 (de) Fredericamycin-derivate
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
ATE378053T1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee